Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 3
1977 1
1978 1
1979 2
1980 1
1981 1
1982 4
1983 6
1984 7
1985 4
1986 12
1987 11
1988 14
1989 14
1990 18
1991 18
1992 33
1993 31
1994 25
1995 41
1996 43
1997 47
1998 55
1999 69
2000 69
2001 111
2002 116
2003 132
2004 117
2005 158
2006 157
2007 204
2008 223
2009 246
2010 309
2011 346
2012 421
2013 462
2014 483
2015 546
2016 583
2017 608
2018 667
2019 740
2020 884
2021 975
2022 1008
2023 892
2024 327

Text availability

Article attribute

Article type

Publication date

Search Results

9,765 results

Results by year

Filters applied: . Clear all
Page 1
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
Li Y, Zhu C, Xie H, Chen Y, Lv W, Xie X, Wang X. Li Y, et al. J Gynecol Oncol. 2023 Mar;34(2):e37. doi: 10.3802/jgo.2023.34.e37. Epub 2023 Jan 10. J Gynecol Oncol. 2023. PMID: 36659832 Free PMC article. Clinical Trial.
It is expected to provide a clinical decision-making tool for adjuvant treatment of patients with high-intermediate risk (HIR) or intermediate risk (IR) EC to better optimise and personalise patient care and increase relapse-free survival. METHODS: The …
It is expected to provide a clinical decision-making tool for adjuvant treatment of patients with high-intermediate risk (HIR) …
Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.
Horiuchi K, Fujimoto M, Hidenori K, Yoshida Y, Noguchi E, Omi Y, Okamoto T. Horiuchi K, et al. World J Surg. 2023 Oct;47(10):2464-2473. doi: 10.1007/s00268-023-07073-7. Epub 2023 Jun 2. World J Surg. 2023. PMID: 37266697 Free PMC article.
We retrospectively collected patient data for analyses of disease-free survivals in the intermediate-risk group patients. RESULTS: We performed surgery on 680 PTC patients from 2010 to 2017. Of them, 297 were classified as the intermediate-risk …
We retrospectively collected patient data for analyses of disease-free survivals in the intermediate-risk group patient …
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J, Gong JF, Wu AW, Shen L. Li J, et al. Eur J Surg Oncol. 2011 Apr;37(4):319-24. doi: 10.1016/j.ejso.2011.01.005. Epub 2011 Jan 31. Eur J Surg Oncol. 2011. PMID: 21277730 Clinical Trial.

RFS at 1, 2 and 3 years were higher in the treatment group than in the control group (100% vs. 90% at 1 year; 96% vs. 57% at 2 years; 89% versus 48% at 3 years, P < 0.001, HR = 0.188). Subgroup analyses showed that adjuvant therapy significantly decreased the ris

…
RFS at 1, 2 and 3 years were higher in the treatment group than in the control group (100% vs. 90% at 1 year; 96% vs. 57% at 2 …
The new "intermediate risk" group: a comparative analysis of the new 2013 ACC/AHA risk assessment guidelines versus prior guidelines in men.
Blaha MJ, Dardari ZA, Blumenthal RS, Martin SS, Nasir K, Al-Mallah MH. Blaha MJ, et al. Atherosclerosis. 2014 Nov;237(1):1-4. doi: 10.1016/j.atherosclerosis.2014.08.024. Epub 2014 Aug 16. Atherosclerosis. 2014. PMID: 25173946
BACKGROUND: The 2013 ACC/AHA Report on the Assessment of Cardiovascular (CVD) Risk redefined "intermediate risk". We sought to critically compare the intermediate risk groups identified by prior guidelines and the new ACC/AHA guidelines. ...The …
BACKGROUND: The 2013 ACC/AHA Report on the Assessment of Cardiovascular (CVD) Risk redefined "intermediate risk". We sought to …
Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer.
Yu JB, Sun Y, Jia AY, Vince RA Jr, Shoag JE, Zaorsky NG, Spratt DE. Yu JB, et al. JAMA Oncol. 2023 Dec 1;9(12):1696-1701. doi: 10.1001/jamaoncol.2023.4267. JAMA Oncol. 2023. PMID: 37796479
Covariables included age, National Comprehensive Cancer Network risk group, rurality, race, facility location, facility type, median income, insurance type or status, and Charlson-Deyo Comorbidity Index. ...By 2020, the most common RT schedule was ultrahypofractionation fo …
Covariables included age, National Comprehensive Cancer Network risk group, rurality, race, facility location, facility type, median …
The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Saad F, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. Nocera L, et al. World J Urol. 2022 Jan;40(1):103-110. doi: 10.1007/s00345-021-03816-0. Epub 2021 Aug 26. World J Urol. 2022. PMID: 34436637
BACKGROUND: Race/ethnicity may predispose to less favorable prostate cancer characteristics in intermediate risk prostate cancer (IR PCa) patients. We tested this hypothesis in a subgroup of IR PCa patients treated with radical prostatectomy (RP). ...In univariable …
BACKGROUND: Race/ethnicity may predispose to less favorable prostate cancer characteristics in intermediate risk prostate canc …
Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.
Ryu SY, Kim MH, Nam BH, Lee TS, Song ES, Park CY, Kim JW, Kim YB, Ryu HS, Park SY, Kim KT, Cho CH, Lee C, Kim SM, Kim BG, Bae DS, Kim YT, Nam JH. Ryu SY, et al. Br J Cancer. 2014 Jan 21;110(2):278-85. doi: 10.1038/bjc.2013.716. Epub 2013 Dec 19. Br J Cancer. 2014. PMID: 24357798 Free PMC article. Clinical Trial.
BACKGROUND: In this study, we sought to identify a criterion for the intermediate-risk grouping of patients with cervical cancer who exhibit any intermediate-risk factor after radical hysterectomy. METHODS: In total, 2158 patients with pathologi …
BACKGROUND: In this study, we sought to identify a criterion for the intermediate-risk grouping of patients with cervic …
A framework for health-related nanomaterial grouping.
Gkika DA, Nolan JW, Vansant EF, Vordos N, Kontogoulidou C, Mitropoulos AC, Cool P, Braet J. Gkika DA, et al. Biochim Biophys Acta Gen Subj. 2017 Jun;1861(6):1478-1485. doi: 10.1016/j.bbagen.2016.08.014. Epub 2016 Aug 27. Biochim Biophys Acta Gen Subj. 2017. PMID: 27578596 Review.
METHODS: Initially, the materials are identified and grouped according to their applications in health/medicine, as well as on their environmentally-friendly potential. ...The toxicity risk assessment shows that the majority pose little to moderate risk, howe …
METHODS: Initially, the materials are identified and grouped according to their applications in health/medicine, as well as on their …
The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria.
Tamada S, Iguchi T, Yasuda S, Kato M, Yamasaki T, Nakatani T. Tamada S, et al. Oncotarget. 2018 Jun 12;9(45):27752-27759. doi: 10.18632/oncotarget.25554. eCollection 2018 Jun 12. Oncotarget. 2018. PMID: 29963234 Free PMC article.
OBJECTIVES: To investigate the necessity of stratifying patients in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center (MSKCC) criteria in a real-world population of patients with metastatic renal cell carcinoma. ...CONCLUSION: P …
OBJECTIVES: To investigate the necessity of stratifying patients in the intermediate-risk group of the Memorial Sloan K …
Early endometrial carcinoma: Experience and outcomes.
Goel P, Singh V, Sharma R, Chaudhary D, Chatterjee A, Dora T, Sancheti S, Goel A, Khandelwal S, Sali AP, Kaur H, Guru A, Kapoor R. Goel P, et al. J Cancer Res Ther. 2023 Apr;19(Supplement):S0. doi: 10.4103/jcrt.jcrt_920_21. J Cancer Res Ther. 2023. PMID: 37147968 Free article.
There were 39 (39.8%), 41 (42.0%), 4 (4.1%), 12 (12.2%) patients in the low risk, intermediate risk (IR), high intermediate risk, and high risk groups, respectively, as per new ESMO risk classification. ...There were 8 deaths in total. Three-yea …
There were 39 (39.8%), 41 (42.0%), 4 (4.1%), 12 (12.2%) patients in the low risk, intermediate risk (IR), high intermediate …
9,765 results